ANDA 202176, held by Apotex. Lansoprazole.
As of Nov 21, 2026, ANDA 202176 (Lansoprazole), held by Apotex, was first approved by FDA on Sep 14, 2012, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 14, 2012 | Original application | Approved | None posted |
| Lansoprazole15MG · capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| Lansoprazole30MG · capsule, delayed rel pellets;oral | Lansoprazole | Rx |
| May 10, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| May 10, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 1, 2017 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 1, 2017 | Supplement 6Labeling · Standard review | Approved | None posted |
| Sep 14, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters